{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:52:23Z","timestamp":1793105543447,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2023.103123","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:32:37Z","timestamp":1696836757000},"page":"103123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Quality of life in sarcoidosis"],"prefix":"10.1016","volume":"149","author":[{"given":"Catharina C.","family":"Moor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogugua Ndili","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Kahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2023.103123_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the world health organization WHOQOL-BREF quality of life assessment. The WHOQOL group","volume":"28","year":"1998","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.jaut.2023.103123_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00408-018-0144-4","article-title":"Needs, perceptions and education in sarcoidosis: a live interactive survey of patients and partners","volume":"196","author":"Moor","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107174","article-title":"Living with sarcoidosis: virtual roundtable dialogue with patients and healthcare professionals","volume":"210","author":"Judson","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib8","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1513\/AnnalsATS.202011-1467OC","article-title":"Barriers to care among patients with sarcoidosis: a qualitative study","volume":"18","author":"Harper","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.jaut.2023.103123_bib9","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000501657","article-title":"Quality of life of couples living with sarcoidosis","volume":"98","author":"Voortman","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.jaut.2023.103123_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11136-013-0438-1","article-title":"A conceptual model of health-related quality of life in sarcoidosis","volume":"23","author":"Victorson","year":"2014","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jaut.2023.103123_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00408-019-00234-3","article-title":"Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability","volume":"197","author":"Hendriks","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/13696998.2017.1351371","article-title":"Economic burden of sarcoidosis in a commercially-insured population in the United States","volume":"20","author":"Rice","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jaut.2023.103123_bib14","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.09.016","article-title":"Work ability before and after sarcoidosis diagnosis in Sweden","volume":"144S","author":"Arkema","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1164\/rccm.201906-1250OC","article-title":"Income and other contributors to poor outcomes in U.S. Patients with sarcoidosis","volume":"201","author":"Harper","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib16","article-title":"Assessment of dyspnea in sarcoidosis using the baseline dyspnea index (BDI) and the transition dyspnea index (TDI)","author":"Obi","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.jaut.2023.103123_bib19","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.rmed.2008.05.001","article-title":"Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis","volume":"102","author":"Gvozdenovic","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib20","doi-asserted-by":"crossref","first-page":"oead009","DOI":"10.1093\/ehjopen\/oead009","article-title":"Health-related quality of life in cardiac sarcoidosis: a systematic review","volume":"3","author":"Quijano-Campos","year":"2023","journal-title":"Eur. Heart J. Open"},{"key":"10.1016\/j.jaut.2023.103123_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","article-title":"Predicting mortality in patients with sarcoidosis awaiting lung transplantation","volume":"124","author":"Shorr","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.05.00083404","article-title":"Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics","volume":"25","author":"Shorr","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib23","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/s41598-019-40030-w","article-title":"Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension","volume":"9","author":"Parikh","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2023.103123_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.14-2546","article-title":"Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series","volume":"148","author":"Bonham","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0165-2021","article-title":"WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2019.03.012","article-title":"Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis","volume":"152","author":"Judson","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215763","article-title":"Scalp hair cortisol and testosterone levels in patients with sarcoidosis","volume":"14","author":"van Manen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2023.103123_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0954-6111(98)90007-5","article-title":"Evaluation of quality of life in sarcoidosis patients","volume":"92","author":"Wirnsberger","year":"1998","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib30","first-page":"96","article-title":"Effect of gender on health related quality of life in sarcoidosis","volume":"27","author":"Bourbonnais","year":"2010","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12890-021-01761-7","article-title":"FeV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients","volume":"21","author":"Frye","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106600","article-title":"Abnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients","volume":"188","author":"Frye","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis","volume":"132","author":"Baughman","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib34","first-page":"117","article-title":"Association between physical functions and quality of life in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89383-1","article-title":"Gender differences in health-related quality of life measured by the Sarcoidosis Health Questionnaire","volume":"11","author":"Gwadera","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2023.103123_bib36","first-page":"837","article-title":"Health related quality of life regarding to gender in sarcoidosis","volume":"33","author":"Dudvarski-Ilic","year":"2009","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.jaut.2023.103123_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000092670","article-title":"Relationship between symptoms and quality of life in a sarcoidosis population","volume":"74","author":"Michielsen","year":"2007","journal-title":"Respiration"},{"key":"10.1016\/j.jaut.2023.103123_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5588\/ijtld.12.0665","article-title":"Effect of obesity on patient-reported outcomes in sarcoidosis","volume":"17","author":"Gvozdenovic","year":"2013","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"Michielsen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The burden of sarcoidosis symptoms from a patient perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133594","article-title":"Cognitive difficulties and health-related quality of life in sarcoidosis: an analysis of the GRADS cohort","volume":"11","author":"Hoth","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib42","first-page":"158","article-title":"Predictors of cough-specific and generic quality of life in sarcoidosis patients","volume":"37","author":"Gvozdenovic","year":"2020","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib43","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.rmed.2018.03.021","article-title":"Sleep disturbance and symptom burden in sarcoidosis","volume":"144S","author":"Benn","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib44","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.5664\/jcsm.10140","article-title":"The prevalence of obstructive sleep apnea in sarcoidosis and its impact on sleepiness, fatigue, and sleep-associated quality of life: a cross-sectional study with matched controls (the OSASA study)","volume":"18","author":"Roeder","year":"2022","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.jaut.2023.103123_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106436","article-title":"Assessment of dyspnea in sarcoidosis using the baseline dyspnea index (BDI) and the transition dyspnea index (TDI)","volume":"191","author":"Obi","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/resp.12359","article-title":"The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis","volume":"19","author":"de Boer","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.jaut.2023.103123_bib47","first-page":"159","article-title":"The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients","volume":"13","author":"Pietinalho","year":"1996","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib48","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1183\/13993003.01369-2015","article-title":"Predictors of objective cough frequency in pulmonary sarcoidosis","volume":"47","author":"Sinha","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00408-017-0040-3","article-title":"The assessment of cough in a sarcoidosis clinic using a validated instrument and a visual analog scale","volume":"195","author":"Judson","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib50","first-page":"267","article-title":"Non-specific bronchial reactivity and ultrastructure of the airway epithelium in patients with sarcoidosis and allergic alveolitis","volume":"131","author":"Laitinen","year":"1983","journal-title":"Eur. J. Respir. Dis. Suppl."},{"key":"10.1016\/j.jaut.2023.103123_bib51","first-page":"118","article-title":"Aspecific bronchial hyperreactivity in pulmonary sarcoidosis","volume":"11","author":"Marcias","year":"1994","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.jaut.2023.103123_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000196408","article-title":"Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage","volume":"62","author":"Ohrn","year":"1995","journal-title":"Respiration"},{"key":"10.1016\/j.jaut.2023.103123_bib53","article-title":"Retrospective study of factors potentially influencing occurrence of cough in Slovak patients with sarcoidosis","volume":"2019","author":"Kovacova","year":"2019","journal-title":"Cancer Res. J."},{"key":"10.1016\/j.jaut.2023.103123_bib54","first-page":"640","article-title":"[A case of radiographic stage 0 sarcoidosis with severe cough]","volume":"46","author":"Nagao","year":"2008","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.jaut.2023.103123_bib55","first-page":"154","article-title":"Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients","volume":"19","author":"Lewis","year":"2002","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib56","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1055\/s-0040-1710080","article-title":"Health-related quality of life in sarcoidosis","volume":"41","author":"Obi","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib57","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study","volume":"138S","author":"Hendriks","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.genhosppsych.2008.04.010","article-title":"Quality of life, anxiety and depression in sarcoidosis","volume":"30","author":"Goracci","year":"2008","journal-title":"Gen. Hosp. Psychiatr."},{"key":"10.1016\/j.jaut.2023.103123_bib59","article-title":"Psychological burden associated with worse clinical outcomes in sarcoidosis","volume":"6","author":"Sharp","year":"2019","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.jaut.2023.103123_bib60","first-page":"65","article-title":"Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis","volume":"28","author":"Elfferich","year":"2011","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm.163.2.2004177","article-title":"Depression in sarcoidosis","volume":"163","author":"Chang","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1164\/ajrccm.163.2.ed2000b","article-title":"Examining the link between sarcoidosis and depression","volume":"163","author":"Curtis","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.2044-8287.2012.02094.x","article-title":"Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis","volume":"18","author":"de Kleijn","year":"2013","journal-title":"Br. J. Health Psychol."},{"key":"10.1016\/j.jaut.2023.103123_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.23910","article-title":"Small fibers, large impact: quality of life in small-fiber neuropathy","volume":"49","author":"Bakkers","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2023.103123_bib65","first-page":"33","article-title":"Impact of pain in a Dutch sarcoidosis patient population","volume":"20","author":"Hoitsma","year":"2003","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib66","first-page":"PA3274","article-title":"Functional and symptomatic burden of small fiber neuropathy in sarcoidosis","volume":"50","author":"Culver","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.jaut.2023.103123_bib67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCP.0000000000000597","article-title":"Nonorgan manifestations of sarcoidosis","volume":"25","author":"Tavee","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"Tavee","year":"2011","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.jaut.2023.103123_bib69","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/pathophysiology28040035","article-title":"Small fiber neuropathy in sarcoidosis","volume":"28","author":"Gavrilova","year":"2021","journal-title":"Pathophysiology"},{"key":"10.1016\/j.jaut.2023.103123_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020390","article-title":"Comprehensive care for patients with sarcoidosis","volume":"9","author":"Moor","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib71","unstructured":"FDA. US department of health and human services, Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (2009). Available from: www.fda.gov."},{"key":"10.1016\/j.jaut.2023.103123_bib72","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fmed.2017.00226","article-title":"Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis","volume":"4","author":"Moor","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01531-2021","article-title":"The use of online visual analogue scales in idiopathic pulmonary fibrosis","volume":"59","author":"Moor","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib74","first-page":"2","article-title":"Patient reported outcome measures (PROMs) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jaut.2023.103123_bib76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.jaut.2023.103123_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12931-018-0808-x","article-title":"Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L","volume":"19","author":"Szentes","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.jaut.2023.103123_bib89","series-title":"The World Health Organization Quality of Life (WHOQOL)","author":"Who","year":"2012"},{"key":"10.1016\/j.jaut.2023.103123_bib77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life","volume":"168","author":"Cox","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaut.2023.103123_bib82","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure","volume":"191","author":"Judson","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib90","first-page":"60","article-title":"The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS","volume":"30","author":"Kalkanis","year":"2013","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib83","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS)","volume":"9","author":"De Vries","year":"2004","journal-title":"Br. J. Health Psychol."},{"key":"10.1016\/j.jaut.2023.103123_bib84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2010.09.014","article-title":"The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis","volume":"105","author":"Hoitsma","year":"2011","journal-title":"Respir. Med."},{"issue":"Suppl B","key":"10.1016\/j.jaut.2023.103123_bib88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St george's respiratory questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib91","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00408-020-00394-7","article-title":"The St. George's respiratory questionnaire in pulmonary sarcoidosis","volume":"198","author":"Lo","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105936","article-title":"Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis","volume":"165","author":"Vis","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib98","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1183\/09031936.00060612","article-title":"Established and experimental medical therapy of pulmonary sarcoidosis","volume":"41","author":"Baughman","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib112","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib122","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib124","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib128","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2023.103123_bib133","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib141","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records","volume":"13","author":"Chopra","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib139","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib79","first-page":"183","article-title":"Quality of life in sarcoidosis: a comparison between members of a patient organisation and a random sample","volume":"15","author":"De Vries","year":"1998","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib80","first-page":"701","article-title":"WHOQOL-bREF questionnaire as a measure of quality of life in sarcoidosis","volume":"37","author":"Alilovic","year":"2013","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.jaut.2023.103123_bib85","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis","volume":"105","author":"de Kleijn","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib86","first-page":"333","article-title":"Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the Small Fiber Neuropathy Screening List (SFNSL) in sarcoidosis","volume":"35","author":"Voortman","year":"2018","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib87","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MCP.0b013e32832d0403","article-title":"Fatigue in sarcoidosis: a systematic review","volume":"15","author":"de Kleijn","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib92","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF02142475","article-title":"[Therapeutic experiences with dexamethasone in pulmonary sarcoidosis (Boeck's disease)]","volume":"123","author":"Wurm","year":"1960","journal-title":"Beitr Klin Tuberk Spezif Tuberkuloseforsch"},{"key":"10.1016\/j.jaut.2023.103123_bib96","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.1953.03690040012005","article-title":"Local injection of hydrocortisone and cortisone into skin lesions of sarcoidosis","volume":"152","author":"Sullivan","year":"1953","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jaut.2023.103123_bib97","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2019","article-title":"The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review","volume":"29","author":"Vis","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib99","doi-asserted-by":"crossref","unstructured":"C.E. Broos, L.H.C. Poell, C.W.N. Looman, J. In \u2019t Veen, M. Grootenboers, R. Heller, et al., No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis, Respir. Med. 2018 May:138S:S31-S37. doi: 10.1016\/j.rmed.2017.10.022. Epub 2017 Oct 31.","DOI":"10.1016\/j.rmed.2017.10.022"},{"key":"10.1016\/j.jaut.2023.103123_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jaut.2023.103123_bib101","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jaut.2023.103123_bib102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Sarcoidosis","volume":"42","author":"Corticosteroids","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2023.103123_bib103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.jaut.2023.103123_bib105","first-page":"7","article-title":"Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids","author":"Entrop","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.jaut.2023.103123_bib106","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib107","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","volume":"138S","author":"Broos","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib110","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib111","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib113","doi-asserted-by":"crossref","DOI":"10.1177\/14799731211031935","article-title":"Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population","volume":"18","author":"Kahlmann","year":"2021","journal-title":"Chron. Respir. Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib114","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/resp.14001","article-title":"Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: a retrospective 'target trial' emulated with Swedish real-world data","volume":"26","author":"Rossides","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.jaut.2023.103123_bib115","first-page":"11","article-title":"Efficacy and tolerability of methotrexate and methylprednisolone in a comparative assessment of the primary and long-term outcomes in patients with pulmonary sarcoidosis","author":"Gavrysyuk","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.jaut.2023.103123_bib116","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2169\/internalmedicine.52.0976","article-title":"Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis","volume":"52","author":"Isshiki","year":"2013","journal-title":"Intern. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib117","doi-asserted-by":"crossref","unstructured":"R. Vis, H. Mathijssen, R.G.M. Keijsers, E.M.W. van de Garde, M. Veltkamp, F. Akdim, et al., Prednisone vs methotrexate in treatment naive cardiac sarcoidosis, J. Nucl. Cardiol. (2023).Aug;30(4):1543-1553. doi: 10.1007\/s12350-022-03171-6. Epub 2023 Jan 14.","DOI":"10.1007\/s12350-022-03171-6"},{"key":"10.1016\/j.jaut.2023.103123_bib118","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib119","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib121","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.jaut.2023.103123_bib125","unstructured":"E.E. Lower, M. Sturdivant, L. Grate, R.P. Baughman, Use of third-line therapies in advanced sarcoidosis, Clin. Exp. Rheumatol. 2020 Sep-Oct;38(5):834-840. Epub 2019 Nov 20."},{"key":"10.1016\/j.jaut.2023.103123_bib126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2023.103123_bib127","first-page":"1","article-title":"Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update","author":"Obi","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2023.103123_bib130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jaut.2023.103123_bib131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib132","first-page":"S47","article-title":"Tumor necrosis factor inhibition in treating sarcoidosis: the American experience","volume":"13","author":"Baughman","year":"2007","journal-title":"Revista Portuguesa de Pneumonologia 2007"},{"key":"10.1016\/j.jaut.2023.103123_bib134","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir","year":"2022","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.jaut.2023.103123_bib135","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib136","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jaut.2023.103123_bib137","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09273948.2012.762982","article-title":"Successful treatment of ocular sarcoidosis with rituximab","volume":"21","author":"Beccastrini","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jaut.2023.103123_bib138","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-37-4-776","article-title":"Effect of acthar-c (ACTH) in sarcoidosis","volume":"37","author":"Miller","year":"1952","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib140","first-page":"192","article-title":"Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study","volume":"35","author":"Judson","year":"2018","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib142","first-page":"1","article-title":"Outcomes of repository corticotropin gel for ocular sarcoidosis","author":"Oh","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jaut.2023.103123_bib143","doi-asserted-by":"crossref","first-page":"90","DOI":"10.36469\/jheor.2022.33295","article-title":"Understanding predictors of response to repository corticotropin injection treatment among patients with advanced symptomatic sarcoidosis","volume":"9","author":"Bindra","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.jaut.2023.103123_bib144","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0147-2019","article-title":"Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2021.12.016","article-title":"Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib","volume":"98","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib146","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2023.103123_bib147","doi-asserted-by":"crossref","unstructured":"W. Damsky, D. Thakral, M.K. McGeary, J. Leventhal, A. Galan, B. King, Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare, J. Am. Acad. Dermatol. 2020 Mar;82(3):612-621. doi: 10.1016\/j.jaad.2019.05.098. Epub 2019 Jun 8.","DOI":"10.1016\/j.jaad.2019.05.098"},{"key":"10.1016\/j.jaut.2023.103123_bib148","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.jaut.2023.103123_bib149","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2023.103123_bib150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/1756-185X.14441","article-title":"Tofacitinib for sarcoidosis, a new potential treatment","volume":"25","author":"Xu","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2023.103123_bib151","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib152","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of multiorgan sarcoidosis with tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.jaut.2023.103123_bib153","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib154","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"Baughman","year":"2009","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib155","first-page":"139","article-title":"Ambrisentan for sarcoidosis associated pulmonary hypertension","volume":"28","author":"Judson","year":"2011","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib156","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1086\/688775","article-title":"Tadalafil therapy for sarcoidosis-associated pulmonary hypertension","volume":"6","author":"Ford","year":"2016","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.jaut.2023.103123_bib157","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib158","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib160","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106371","article-title":"Antifibrotic drugs for pulmonary sarcoidosis: a treatment in search of an indication","volume":"180","author":"Judson","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib162","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","article-title":"From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis","volume":"22","author":"Bonham","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib163","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PAS.0b013e3182785a2d","article-title":"End-stage sarcoid lung disease is distinct from usual interstitial pneumonia","volume":"37","author":"Xu","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jaut.2023.103123_bib164","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib165","first-page":"11","article-title":"Comparative analysis of gene expression in fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","author":"Kamp","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2023.103123_bib166","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib167","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib168","series-title":"Effects of Nintedanib on Dyspnea, Cough and Quality of Life in Patients with Progressive Fibrosing Interstitial Lung Diseases: Findings from the INBUILD Trial","article-title":"Om behalf of the INBUILD trial investigators","author":"Swigris Jj","year":"2020"},{"key":"10.1016\/j.jaut.2023.103123_bib169","series-title":"Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","author":"Ghazipura","year":"2022"},{"key":"10.1016\/j.jaut.2023.103123_bib170","article-title":"Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib171","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"Lower","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2023.103123_bib172","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial","volume":"45","author":"Lower","year":"2013","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.jaut.2023.103123_bib173","first-page":"235","article-title":"The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis","volume":"22","author":"Wagner","year":"2005","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib174","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1200\/JCO.2003.06.156","article-title":"Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report","volume":"21","author":"Bruera","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2023.103123_bib175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/archinte.161.3.411","article-title":"A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease","volume":"161","author":"Breitbart","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib176","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17843286.2016.1200816","article-title":"Long-term methylphenidate intake in chronic fatigue syndrome","volume":"71","author":"Blockmans","year":"2016","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.jaut.2023.103123_bib177","article-title":"Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial","volume":"8","author":"Atkins","year":"2021","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.jaut.2023.103123_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018532","article-title":"Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol","volume":"7","author":"Atkins","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaut.2023.103123_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-007-0996-4","article-title":"Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis","volume":"197","author":"Peterson","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaut.2023.103123_bib180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"Parambil","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib181","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib182","first-page":"981","article-title":"[Sarcoid neuropathy]","volume":"66","author":"Koga","year":"2014","journal-title":"Brain Nerve"},{"key":"10.1016\/j.jaut.2023.103123_bib183","first-page":"73","article-title":"Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab","volume":"23","author":"Hoitsma","year":"2006","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib184","article-title":"Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis","volume":"39","author":"Raasing","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2014.892072","article-title":"ARA 290 for treatment of small fiber neuropathy in sarcoidosis","volume":"23","author":"van Velzen","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.jaut.2023.103123_bib186","doi-asserted-by":"crossref","first-page":"BIO52","DOI":"10.1167\/iovs.16-21291","article-title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","volume":"58","author":"Culver","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jaut.2023.103123_bib187","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2119\/molmed.2012.00332","article-title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","volume":"18","author":"Heij","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib188","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/PR9.0000000000000566","article-title":"Targeting the innate repair receptor to treat neuropathy","volume":"1","author":"Dahan","year":"2016","journal-title":"Pain Rep."},{"key":"10.1016\/j.jaut.2023.103123_bib189","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2119\/molmed.2014.00215","article-title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","volume":"20","author":"Brines","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","article-title":"Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis","volume":"952","author":"Agnello","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.jaut.2023.103123_bib191","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib192","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00534-2020","article-title":"Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial","volume":"6","author":"Fraser","year":"2020","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.jaut.2023.103123_bib194","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1183\/09031936.00081512","article-title":"Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease","volume":"42","author":"Huppmann","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib195","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: review and experience-based recommendations","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.jaut.2023.103123_bib196","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib197","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000486964","article-title":"Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study","volume":"95","author":"Lingner","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.jaut.2023.103123_bib198","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial","volume":"38","author":"Naz","year":"2018","journal-title":"J. Cardiopulm. Rehabil. Prev."},{"key":"10.1016\/j.jaut.2023.103123_bib199","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000514917","article-title":"The short- and long-term impact of pulmonary rehabilitation in subjects with sarcoidosis: a prospective study and review of the literature","volume":"100","author":"Guber","year":"2021","journal-title":"Respiration"},{"key":"10.1016\/j.jaut.2023.103123_bib200","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2020.1730137","article-title":"High-intensity resistance training in newly diagnosed sarcoidosis- an exploratory study of effects on lung function, muscle strength, fatigue, dyspnea, health-related quality of life and lung immune cells","volume":"7","author":"Kullberg","year":"2020","journal-title":"Eur. Clin. Respir. J."},{"key":"10.1016\/j.jaut.2023.103123_bib203","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00085-2017","article-title":"Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis","volume":"4","author":"Saketkoo","year":"2018","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.jaut.2023.103123_bib204","doi-asserted-by":"crossref","unstructured":"V. Kahlmann, C.C. Moor, S.J. van Helmondt, R.L.M. Mostard, M.L. van der Lee, J.C. Grutters, et al., Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial, Lancet Respir. Med. (2023).Mar;11(3):265-272. doi: 10.1016\/S2213-2600(22)00387-3. Epub 2022 Nov 22.","DOI":"10.1016\/S2213-2600(22)00387-3"},{"key":"10.1016\/j.jaut.2023.103123_bib193","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation","volume":"188","author":"Spruit","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2023.103123_bib201","article-title":"Telerehabilitation for chronic respiratory disease","volume":"1","author":"Cox","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jaut.2023.103123_bib202","article-title":"Effect of a Telerehabilitation program in sarcoidosis","volume":"39","author":"Cerdan de Las Heras","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2023.103123_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2023.101062","article-title":"Design and rationale of a pilot randomized clinical trial investigating the use of a mHealth app for sarcoidosis-associated fatigue","volume":"32","author":"Chandler","year":"2023","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.jaut.2023.103123_bib206","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000501","article-title":"Nutrition and corticosteroids in the treatment of sarcoidosis","volume":"24","author":"Bast","year":"2018","journal-title":"Curr. Opin. Pulm. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T11:40:16Z","timestamp":1738496416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841123001324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":206,"alternative-id":["S0896841123001324"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103123","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life in sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103123"}}